# Befotertinib

Source: https://onco.cc/drugs/befotertinib/  
OnCo record `befotertinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.

## Summary

Befotertinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Betta Pharmaceuticals Co., Ltd., in non-small-cell lung cancer. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral kinase inhibitor
- Mechanism: A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Befotertinib: https://clinicaltrials.gov/search?intr=Befotertinib

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)
- trials: [Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI](https://onco.cc/trials/nct07181499/)

---
JSON: https://onco.cc/api/v1/entities/befotertinib.json